Not Yet Recruiting PHASE2 INTERVENTIONAL 4-arm NCT07301320

Epetraborole in Patients With Mycobacterium Abscessus Lung Disease (REBOUND)

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Prospective, Investigator-Initiated Trial to Assess the Efficacy, Safety, and Pharmacokinetics of Epetraborole in Patients With Mycobacterium Abscessus Lung Disease: REBOUND Study

Sponsor: AN2 Therapeutics, Inc

Conditions Mycobacterium Abscessus Infection

Interventions Epetraborole Placebo

Updated 2 times since 2026 Last updated: Feb 20, 2026 Started: Mar 31, 2026 Primary completion: Jul 31, 2027 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Mycobacterium Abscessus Infection, this trial is actively recruiting participants. The trial is conducted by AN2 Therapeutics, Inc and has accumulated 2 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

2 versions recorded

Feb 2026 — Present [monthly]

Not Yet Recruiting PHASE2
Jan 2026 — Feb 2026 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AN2 Therapeutics, Inc
Kevin Winthrop

Data source: Oregon Health and Science University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Portland, United States